UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2018

Commission File Number 001-33042

ROSETTA GENOMICS LTD.

(Translation of registrant’s name into English)

10 Plaut Street, Science Park

Rehovot 76706, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Rosetta Genomics Ltd.

~~The~~On ~~extraordinary~~April ~~general~~16, ~~meeting~~2018, ~~of shareholders of~~ Rosetta Genomics Ltd. (the “Company”) ~~that~~received ~~was~~a ~~summoned~~notification ~~for~~letter ~~April~~from ~~17, 2018, has been adjourned to Thursday, April 26, 2018 at 10:00 AM (PT) in order to provide additional time for~~ the ~~solicitation~~NASDAQ ofStock ~~votes~~Market inindicating ~~favor~~that ofit ~~the~~has ~~proposed~~not ~~merger~~paid certain offees ~~the~~required ~~Company~~by ~~with~~Listing aRule ~~subsidiary~~5250(f) ~~of Genoptix, Inc. The adjourned meeting will be held at 25901 Commercentre Dr., Lake Forest, CA 92630. The Company~~ and ~~Genoptix~~is, ~~Inc.~~therefore, ~~have~~subject ~~entered into Amendment No. 2~~ to ~~Agreement~~delisting ~~and~~proceedings ~~Plan~~if ofit ~~Merger,~~does ~~Amendment~~not ~~No.~~pay 2the tobalance ~~Convertible Debenture~~of ~~and Warrant Termination Agreement, Amendment No. 2 to Expense Reimbursement Waiver Agreement, and Amendment Number Three~~its tooutstanding ~~Loan~~fees ~~and Security Agreement,~~ in ~~order to permit necessary extensions of the shareholder meeting date and outside date for completing the transaction~~full.

The ~~matter~~Company tomay beappeal ~~voted upon at~~ the ~~adjourned~~Nasdaq Staff’s ~~meeting,~~determination ~~and~~to ~~the~~a ~~record~~Hearings ~~date~~Panel ~~for~~ (the ~~shareholders~~“Panel”) ~~entitled~~by tono ~~vote~~later atthan ~~the~~April ~~meeting~~23, ~~will~~2018, ~~remain~~pursuant ~~unchanged.~~to ~~For~~the ~~information~~procedures ~~regarding~~set forth in the ~~matter~~Nasdaq toListing beRule ~~voted~~5800 ~~upon~~Series, atby ~~the~~paying ~~adjourned~~a ~~meeting~~$10,000 ~~see~~non-refundable ~~the~~hearing ~~Company’s~~fee. ~~proxy~~A ~~statement~~hearing ~~filed~~request onwill ~~Form~~stay ~~6-K~~the ~~with~~suspension of the ~~U.S.~~Company’s ~~Securities~~ securities and ~~Exchange~~the ~~Commission~~filing onof ~~March~~the ~~13,~~Form ~~2018~~25-NSE pending the Panel’s decision.

OnIf ~~April~~the ~~17,~~Company ~~2018,~~elects ~~Rosetta~~not ~~Genomics~~to ~~Ltd.~~appeal, then ~~issued~~trading aof ~~press~~its ~~release~~common ~~notifying~~stock ~~shareholders~~will ofbe suspended at the ~~new~~opening ~~meeting~~of ~~date~~business ~~and~~on ~~urging~~April ~~shareholders~~25, to2018, ~~vote~~and ina ~~favor~~Form of25-NSE ~~the~~will ~~proposed merger~~be filed with the ~~Genoptix,~~Securities ~~Inc.~~and AExchange ~~copy~~Commission of(the “SEC”), which will remove the ~~press~~Company’s ~~release~~securities isfrom ~~filed~~listing asand registration ~~Exhibit~~on 99The Nasdaq Stock Market.1 The Company’s securities may be eligible to ~~this~~continue ~~Form~~to ~~6-K~~be ~~and~~quoted ~~incorporated~~on bythe ~~reference~~OTC Bulletin ~~herein~~Board or in the “Pink Sheets.”

~~Exhibits~~The Company is also subject to de-listing for failing to comply with Nasdaq’s minimum stockholders’ equity requirement. On October 24, 2017, Staff notified the Company that it did not comply with Listing Rule 5550(b) (the “Rule”), which requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. On December 19, 2017, Rosetta Genomics Ltd. (the “Company”) received a notification letter from the NASDAQ Stock Market (“Nasdaq”) informing the Company that Nasdaq had determined to grant the Company an extension to regain compliance with Listing Rule 5550(b) (the “Rule”). The terms of the extension were as follows: on or before April 23, 2018, the Company must have closed on the previously announced transaction with Genoptix, Inc., which would effectively result in the delisting of the Company from the Nasdaq Capital Market. If the transaction with Genoptix, Inc., failed to close on or before April 23, 2018, the Company would have to raise sufficient equity to comply with the Rule. In the event the Company does not satisfy the terms, Nasdaq will provide written notification that its securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a Listing Qualifications Panel.

Exhibit Number		Description of Exhibit
99.1		Press release dated April 17, 2018.

As part of Staff’s ongoing review or in response to any submissions the Company has made or will make, Staff may identify additional deficiencies under Nasdaq's rules. The Company will be formally notified of any such additional deficiencies and the basis for them.

The information contained in this Report (including the exhibits hereto) is hereby incorporated by reference into the Company’s Registration Statements on Form F-3, File Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338, 333-207697 and 333-210366, and Form S-8, File Nos. 333-141525, 333-147805, 333-165722 and 333-191072, to the extent not superseded by documents or reports subsequently filed or furnished.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROSETTA GENOMICS LTD.
Date: April 17, 2018	By:	/s/ Ron Kalfus
Date: April 19, 2018	By:	/s/ Ron Kalfus
		Ron Kalfus Chief Financial Officer

Filing Compare · Rosetta Genomics Ltd.